{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 19,
  "pageCount": 27,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights the drug's targeted delivery to the site of infection (alveolar macrophages).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/19",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Results suggest therapeutically relevant doses of epetraborole may be achieved in macrophages at doses that are substantially lower than MTD in previous trials",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da3bd7ab-b4f3-4d71-bae9-67d40eabe444",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.35,
        "y": 0.1
      },
      "kind": "chart",
      "text": "Composite AUC(0-t) (ng·h/mL) for Plasma vs AM",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "152e1839-bc88-4c34-968a-a54c4382b5f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Results from Phase 1 trial showed the concentration in lung macrophages (site of NTM infection) was 5x higher than in plasma",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceda2af5-1f74-4864-a96f-3861eebb9447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.45,
        "y": 0.65
      },
      "kind": "source-note",
      "text": "1AUC based on concentrations at 2,6, and 12-hour timepoints. AM = alveolar macrophages",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca0a7dc5-29b2-4766-970b-6340231fc70b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Favorable pharmacokinetics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30d4bb4c-fae3-4745-be96-9df21b0f77a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}